Usefulness of contrast‐enhanced ultrasonography using <scp>S</scp>onazoid for the assessment of therapeutic response to percutaneous radiofrequency ablation for hepatocellular carcinoma

Nishigaki, Yoichi; Hayashi, Hideki; Tomita, Eiichi; Suzuki, Yusuke; Watanabe, Naoki; Watanabe, Satoshi; Watanabe, Chiaki; Takagi, Yui; Kato, Tomohiro; Naiki, Taku

doi:10.1111/hepr.12370

Cited by 35 publications

(40 citation statements)

References 39 publications

(87 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among the included studies in this meta-analysis, SH U 508A, 12,13,18 SonoVue 14,19 and Sonazoid 11,15,17,23 were used in as the contrast agents. SH U 508A is the first agent approved by Europe and Canada for radiology application.…”

Section: Discussionmentioning

confidence: 99%

“…From Figure 2c, we can also find that Sonazoid is more frequently used than other agents in recent years. The possible reasons for this situation are that Sonazoid permits real-time and precise observation of the hepatic hemodynamics during a long period, 11 and Sonazoid has more stable Kupffer phase image than SH U 508A. 15 However, as regards comparison between Sonazoid and SH U 508A, a bias may arise from evolution of ultrasonography equipment.…”

Section: Discussionmentioning

confidence: 99%

“…11 studies of which CEUS was not the only detection method, 11 meeting abstracts, 4 non-English studies and 3 without extractable data were excluded. Finally, a total of 12 studies [11][12][13][14][15][16][17][18][19][20]22,23 were enrolled in the meta-analysis. Table 1 shows the characteristics of the eligible studies.…”

Section: Study Selectionmentioning

confidence: 99%

“…Contrast-enhanced ultrasonography (CEUS) due to its advantages of moderate price and ability to repeated assessment and high spatial resolution is not only used in evaluation of the local response but also in follow-up of patients. 11 A number of studies have investigated the usefulness of CEUS in evaluation of the post-surgical curative effects of RFA for HCC; [11][12][13][14][15][16][17][18][19][20] however, inconsistent results have been reported. This study therefore aimed to summarize the previously published studies on the role of CEUS in evaluation of therapeutic response of RFA for HCC and systematically analyze the effect.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Contrast-enhanced ultrasonography used for post-treatment responses evaluation of radiofrequency ablations for hepatocellular carcinoma: a meta-analysis

Shi

Ding

et al. 2016

BJR

View full text Add to dashboard Cite

Weixiang Shi and Ying He should both be regarded as first authors.Objective: This meta-analysis aims to analyze the usefulness of contrast-enhanced ultrasonography (CEUS) for posttreatment responses evaluation of radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC) management. Methods: Literature retrieval in three databases PubMed, Embase and Cochrane Library was conducted up to September 2015, with pre-defined criteria. The technical success rate, local tumour recurrence and local tumour progression were the measurement indexes. Cochran's Q test and I 2 were used for heterogeneity detection. Subgroup analyses were performed for complete ablation rate stratified by study designs, contrast agents and post-operative testing time points. Statistical analyses were conducted using Stata® 12.0 software (Stata Corporation, College Station, TX). Results: 12 studies consisting of 772 patients were included in this study. The CEUS-evaluated success rate of RFA for HCCs was 91%. The proportion of ablative margin ,5 mm was 53%. The local tumour recurrence rate and local tumour progression rate were 4% and 8%, respectively. Subgroup analysis indicated that the CEUS-assessed technical success rate with Sonazoid™ (Daiichi-Sankyo, Tokyo, Japan) as the contrast agent was higher (95%) than those with other agents [SH U 508A (Schering AG, Berlin, Germany) 86%; SonoVue (Bracco SpA, Milan, Italy) 87%]. The success rate assessed within 24 h (94%) after treatment was higher than longer time (1-3 days 86%; 1 month 91%). Conclusion:The meta-analysis showed that the CEUSevaluated success rate of RFA for HCCs was 91%. The local tumour recurrence rate and local tumour progression rate were 4% and 8%, respectively. Advances in knowledge: Using meta-analysis, the study provided more reliable assessment of usefulness of CEUS, which could provide guidelines for HCC treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Study Selectionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Contrast-enhanced ultrasonography used for post-treatment responses evaluation of radiofrequency ablations for hepatocellular carcinoma: a meta-analysis

Shi

Ding

et al. 2016

BJR

View full text Add to dashboard Cite

show abstract

“…Currently, contrast-enhanced ultrasonography is a potential and helpful medical protocol that may be used as a pain-free and non-invasive method of diagnosing adenocarcinoma. A previous study has documented the diagnosis of hepatocellular and cholangiocellular carcinomas or metastatic adenocarcinoma of the liver using contrast-enhanced ultrasonography and demonstrated contrast-enhanced ultrasonography was efficient at diagnosing tumors of the liver (27). However, to the best of our knowledge, there have been no studies analyzing the effectiveness of contrast-enhanced ultrasound used in the diagnosis of early-stage primary adenocarcinoma.…”

Section: Contrast-enhanced Ultrasound: Large Cell Carcinomamentioning

confidence: 99%

Contrast-enhanced ultrasound with a novel nanoparticle contrast agent for clinical diagnosis in patients with non-small cell lung cancer

Han

Jing

2017

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Abstract. Non-small cell lung cancer (NSCLC) initiates in the non-small cells of the lung and is one of the most common types of human cancer. It is known for its rapid growth, easy migration, invasion and reoccurrence, and has the highest incidence rate of all types of cancer. Early detection of NSCLC is difficult to achieve and this is the primary reason for low survival rates in NSCLC. Contrast-enhanced ultrasound is the most common application for evaluating patients diagnosed with NSCLC. In the present study, a contrast-enhanced ultrasound combined with nanoparticles was performed with the aim of identifying patients with NSCLC at an early stage. The present study evaluated the effectiveness of administering a nanoparticle contrast agent through respiration in combination with enhanced ultrasound at improving image quality compared with traditional ultrasound. This maybe a novel method of detecting early-stage tumors in patients. There are numerous benefits to conducting diagnoses of NSCLC using contrast-enhanced ultrasound. It is a non-invasive imaging modality, induces little pain, has a low cost, an extensive range and produces high-resolution images. This means that it is safer and more beneficial to use in patients with NSCLC than conventional imaging examinations, including X-ray and bronchoscopy. Furthermore, the nanoscale microbubble contrast agent containing liposome-encapsulated epidermal growth factor receptor was inhaled by nebulization, which may lead to an enhanced ultrasound image. The sensitivity of contrast-enhanced ultrasound was investigated in mice with early stage NSCLC. The results indicated that ultrasound administrated with nanoscale microbubble enhanced sensitivity and improved image quality compared with simple ultrasound. Furthermore, enhanced ultrasound resulted in a reliable and sensitive assessment of tumor mass in early-stage tumors. Altogether, contrast-enhanced ultrasound facilitated the efficient detection of NSCLC in patients in situ at an early stage. This protocol improved the understanding of the pathophysiology of NSCLC and may be applied in the detection of early-stage tumors in patients suspected of having cancer.

show abstract

Contrast‐enhanced ultrasound for hepatocellular carcinoma: Focusing on unique benefits and indications

Wang

2019

Adv in Digestive Medicine

View full text Add to dashboard Cite

Usefulness of contrast‐enhanced ultrasonography using Sonazoid for the assessment of therapeutic response to percutaneous radiofrequency ablation for hepatocellular carcinoma

Abstract: The assessment with CEUS at 3 h after the PRFA procedure was successful in the majority of the patients, and it yielded a very low rate of local recurrence.

Cited by 35 publications

References 39 publications

Contrast-enhanced ultrasonography used for post-treatment responses evaluation of radiofrequency ablations for hepatocellular carcinoma: a meta-analysis

Contrast-enhanced ultrasonography used for post-treatment responses evaluation of radiofrequency ablations for hepatocellular carcinoma: a meta-analysis

Contrast-enhanced ultrasound with a novel nanoparticle contrast agent for clinical diagnosis in patients with non-small cell lung cancer

Contrast‐enhanced ultrasound for hepatocellular carcinoma: Focusing on unique benefits and indications

Contact Info

Product

Resources

About